Global Human Immunodeficiency Virus (HIV) statistics by the World Health Organization
(WHO) for the year 2017 was estimated to be 36.9 (31.1-43.9) million. Antiviral drug …

Rigorous research over the years has produced a number of potential drugs that target
various stages of the human immunodeficiency virus type I (HIV-I) life cycle. Despite …

Highly active antiretroviral therapy combines antiviral drugs targeting different steps in the
HIV replication cycle in order to reduce viral loads in patients to undetectable levels. Since …

The arsenal of drugs in the fight against AIDS is rapidly diminishing as the HIV becomes
resistant to the available reverse transcriptase and protease inhibitors. After killing millions …

Abstract Purpose of the Review The complex multistep life cycle of HIV allows it to proliferate
within the host and integrate its genome in to the host chromosomal DNA. This provirus can …

HIV-1 integrase, a member of a polynucleotidyl transferases superfamily, catalyzes the
insertion of the viral DNA into the genome of host cells. It has emerged as a potential target …

In recent years, HIV‐1 integrase (IN) has become an attractive target for designing
antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated …

HIV-1 integrase catalyzed the insertion of viral DNA into the genome of human cells in the
process of retrotranscription. Integrase is an attractive target for HIV-1 treatment due to the …

AIDS caused by the infection of HIV is a prevalent problem today. Rapid development of
drug resistance to existing drug classes has called for the discovery of new targets. Within …

Integrase (IN) represents a clinically validated target for the development of antivirals
against human immunodeficiency virus (HIV). Inhibitors with a novel structure core are …